<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04236778</url>
  </required_header>
  <id_info>
    <org_study_id>VE303-01</org_study_id>
    <nct_id>NCT04236778</nct_id>
  </id_info>
  <brief_title>First-in-human Study of VE303 in Healthy Adult Volunteers</brief_title>
  <official_title>A Phase 1a/1b, First-in-human, Open-label Study of Escalating Doses of VE303 in Healthy Adult Volunteers With or Without Vancomycin Pre-treatment to Evaluate Safety, Dosing, and Pharmacodynamics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vedanta Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vedanta Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to evaluate safety and tolerability of a range of doses of VE303 in&#xD;
      healthy adult volunteers. The study also evaluated pharmacokinetics of intestinal&#xD;
      colonization by the VE303 strains and pharmacodynamics of recovery of the gut microbiota&#xD;
      after administration of antibiotics followed by a course of VE303.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      VE303 is a rationally-defined bacterial consortium candidate being developed for the&#xD;
      prevention of recurrent C. difficile infection. VE303 consists of 8 types of clonal human&#xD;
      commensal bacteria strains selected for their ability to provide colonization resistance to&#xD;
      C. difficile and manufactured under GMP conditions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 28, 2017</start_date>
  <completion_date type="Actual">March 11, 2019</completion_date>
  <primary_completion_date type="Actual">March 11, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>This Phase 1a/1b, first-in-human, open-label, single-center, dose-escalation study will evaluate the safety and microbiota changes induced by ingestion of VE303 following administration of oral vancomycin and VE303 administered without vancomycin pre-treatment in healthy adult subjects. Approximately 48 subjects are anticipated for enrollment, unless intermediate cohorts are required, in which case, up to an additional 18 subjects (for a total of approximately 66 subjects) may be enrolled.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of VE303 measured by incidence adverse events (AEs)</measure>
    <time_frame>12 months post-dose</time_frame>
    <description>Measured in terms of incidence of AEs according to CTCAE V4.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability of VE303 using modified PROMIS questionnaire (v1.0)</measure>
    <time_frame>12 months post-dose</time_frame>
    <description>Characterized the highest well tolerated dose regimen of VE303 using modified PROMIS questionnaire (v1.0)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the colonization of the intestinal microbiota with VE303 component bacteria</measure>
    <time_frame>12 months post-dose</time_frame>
    <description>Measurement of VE303 strain colonization in stool samples was performed using a metagenomic sequencing-based bioinformatic approach. A strain-specific marker panel was employed to characterize the relative abundance of VE303 strains in the intestinal microbiota.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the changes in the intestinal microbiota due to VE303 dosing.</measure>
    <time_frame>12 months post-dose</time_frame>
    <description>Measurement of intestinal microbiota due to VE303 dosing was performed using metagenomic sequencing- and metabolomic analysis-based approaches. Thus, focusing on taxonomic and functional changes occurring in the gut.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the metabolomic changes in stool due to VE303 dosing.</measure>
    <time_frame>12 months post-dose</time_frame>
    <description>Quantified changes in pool of metabolite levels (bile acids and short-chain fatty acids) from stool samples</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1 received oral vancomycin followed by a single dose of VE303.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2 received oral vancomycin followed by a single day of 5 doses of VE303.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 3 received oral vancomycin followed by a single day of 10 doses of VE303.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 4 received oral vancomycin followed by 5 days of 10 doses daily of VE303.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 5 received oral vancomycin followed by 14 days of 10 capsules daily of VE303</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 6 received 21 days of 10 doses daily of VE303</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 7 received oral vancomycin followed by 10 doses of VE303 daily for 2 days, followed by 2 doses of VE303 daily for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 8 received oral vancomycin followed by 10 doses of VE303 daily for 2 days, followed by 2 doses of VE303 daily for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 8 received oral vancomycin followed by 10 doses of VE303 daily for 2 days, followed by 2 doses of VE303 daily for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vancomycin only</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This cohort only received oral vancomycin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VE303</intervention_name>
    <description>The VE303 Drug Product is a live biotherapeutic product (LBP) consisting of 8 clonal human commensal bacterial strains manufactured under GMP conditions.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_label>Cohort 7</arm_group_label>
    <arm_group_label>Cohort 8</arm_group_label>
    <arm_group_label>Cohort 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Vancomycin</intervention_name>
    <description>Vancomycin, when taken by mouth, is used to treat Clostridium difficile-associated diarrhea.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 7</arm_group_label>
    <arm_group_label>Cohort 8</arm_group_label>
    <arm_group_label>Cohort 9</arm_group_label>
    <arm_group_label>Vancomycin only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Subjects who are judged to be in general good health&#xD;
&#xD;
          -  Body mass index between 18.5 and 30 kg/m2&#xD;
&#xD;
          -  Women either of non-child bearing potential or using a highly effective form of&#xD;
             contraception&#xD;
&#xD;
          -  Men using a highly effective method of contraception&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Past or present clinically significant diseases that may affect the outcome of the&#xD;
             study&#xD;
&#xD;
          -  Taking any medications, herbal preparations, or natural substances, live bacteria&#xD;
             products, or food that impacts or alter GI flora&#xD;
&#xD;
          -  Use of proton pump inhibitors or other short or long acting antacid medications&#xD;
&#xD;
          -  Taking or has received an investigation drug or treatment within 60 days of inpatient&#xD;
             admission&#xD;
&#xD;
          -  Known allergies to involved study drugs&#xD;
&#xD;
          -  Chronic constipation or diarrhea&#xD;
&#xD;
          -  History of or active IBD&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pharmaron CPC</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 9, 2020</study_first_submitted>
  <study_first_submitted_qc>January 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2020</study_first_posted>
  <last_update_submitted>January 22, 2020</last_update_submitted>
  <last_update_submitted_qc>January 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

